IL162853A0 - The use of melagatran for the manufacture of a medicament for the treatment of type 1 diabetes mellitus - Google Patents

The use of melagatran for the manufacture of a medicament for the treatment of type 1 diabetes mellitus

Info

Publication number
IL162853A0
IL162853A0 IL16285303A IL16285303A IL162853A0 IL 162853 A0 IL162853 A0 IL 162853A0 IL 16285303 A IL16285303 A IL 16285303A IL 16285303 A IL16285303 A IL 16285303A IL 162853 A0 IL162853 A0 IL 162853A0
Authority
IL
Israel
Prior art keywords
melagatran
medicament
manufacture
treatment
type
Prior art date
Application number
IL16285303A
Other languages
English (en)
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of IL162853A0 publication Critical patent/IL162853A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/37—Digestive system
    • A61K35/39—Pancreas; Islets of Langerhans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Physiology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Nutrition Science (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
IL16285303A 2002-01-23 2003-01-21 The use of melagatran for the manufacture of a medicament for the treatment of type 1 diabetes mellitus IL162853A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE0200198A SE0200198D0 (sv) 2002-01-23 2002-01-23 New use
PCT/SE2003/000087 WO2003061682A1 (en) 2002-01-23 2003-01-21 The use of melagatran for the manufacture of a medicament for the treatment of type 1 diabetes mellitus

Publications (1)

Publication Number Publication Date
IL162853A0 true IL162853A0 (en) 2005-11-20

Family

ID=20286751

Family Applications (1)

Application Number Title Priority Date Filing Date
IL16285303A IL162853A0 (en) 2002-01-23 2003-01-21 The use of melagatran for the manufacture of a medicament for the treatment of type 1 diabetes mellitus

Country Status (14)

Country Link
US (2) US7045502B2 (xx)
EP (1) EP1469874A1 (xx)
JP (1) JP2005516035A (xx)
KR (1) KR20040075096A (xx)
CN (1) CN100430089C (xx)
BR (1) BR0306798A (xx)
CA (1) CA2472241A1 (xx)
IL (1) IL162853A0 (xx)
MX (1) MXPA04007192A (xx)
NO (1) NO20043483L (xx)
NZ (1) NZ533749A (xx)
SE (1) SE0200198D0 (xx)
WO (1) WO2003061682A1 (xx)
ZA (1) ZA200405342B (xx)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0200198D0 (sv) * 2002-01-23 2002-01-23 Astrazeneca Ab New use
KR101955691B1 (ko) 2010-03-30 2019-03-07 베르선 코포레이션 트롬빈 억제제로서의 다중치환된 방향족 화합물
RU2019101889A (ru) 2013-03-15 2019-03-28 Версеон Корпорейшн Полизамещенные ароматические соединения в качестве ингибиторов сериновых протеаз
JP6479749B2 (ja) 2013-03-15 2019-03-06 ヴァーセオン コーポレイション トロンビン阻害剤としてのハロゲノピラゾール
WO2016044662A1 (en) 2014-09-17 2016-03-24 Verseon Corporation Pyrazolyl-substituted pyridone compounds as serine protease inhibitors
EP3261639B1 (en) 2015-02-27 2022-08-24 Verseon International Corporation Substituted pyrazole compounds as serine protease inhibitors
MX2021000472A (es) 2018-07-13 2021-06-23 Verseon Int Corporation Inhibidores de trombina, formulaciones y usos de estos.
AU2022325955A1 (en) 2021-08-11 2024-02-08 Sana Biotechnology, Inc. Genetically modified cells for allogeneic cell therapy to reduce instant blood mediated inflammatory reactions
AU2023220128A1 (en) 2022-02-17 2024-08-22 Sana Biotechnology, Inc. Engineered cd47 proteins and uses thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9301916D0 (sv) 1993-06-03 1993-06-03 Ab Astra New peptides derivatives
TW541316B (en) 1995-12-21 2003-07-11 Astrazeneca Ab Prodrugs of thrombin inhibitors
SE9900070D0 (sv) 1999-01-13 1999-01-13 Astra Ab New use
SE523817C2 (sv) 1999-02-05 2004-05-18 Corline Systems Ab Användning av ett koagulationsförebyggande ämne i samband med transplantation av insulinproducerande celler
US6462021B1 (en) 2000-11-06 2002-10-08 Astrazeneca Ab Use of low molecular weight thrombin inhibitor
SE0200198D0 (sv) * 2002-01-23 2002-01-23 Astrazeneca Ab New use

Also Published As

Publication number Publication date
US20060148720A1 (en) 2006-07-06
SE0200198D0 (sv) 2002-01-23
NZ533749A (en) 2006-02-24
ZA200405342B (en) 2005-09-28
WO2003061682A1 (en) 2003-07-31
JP2005516035A (ja) 2005-06-02
KR20040075096A (ko) 2004-08-26
CN100430089C (zh) 2008-11-05
MXPA04007192A (es) 2004-10-29
CA2472241A1 (en) 2003-07-31
EP1469874A1 (en) 2004-10-27
CN1729010A (zh) 2006-02-01
BR0306798A (pt) 2004-12-07
US20050090424A1 (en) 2005-04-28
NO20043483L (no) 2004-08-20
US7045502B2 (en) 2006-05-16

Similar Documents

Publication Publication Date Title
HK1087337A1 (en) Use of a hif-alpha stabilizing agent for the preparation of medicament for treatment of diabetes
AU2003234529A8 (en) Glp-1 gene delivery for the treatment of type 2 diabetes
EP1510207A4 (en) THERAPEUTIC MEDICAMENT AGAINST DIABETES
IL213809A0 (en) Use of derivatives of n-phenylpiperazin-1-yl-acetamide for the preparation of a pharmaceutical compositions for treatment of diabetes related conditions
EP1469812A4 (en) ORAL INSULIN THERAPY
MXPA03006936A (es) Tratamiento de diabetes mellitus.
IL176259A (en) Use of cystamine in combination with metformin to prepare a cure for diabetes or related complications
HK1087103A1 (en) Anilinopyrazole derivatives useful for the treatment of diabetes
TWI345975B (en) Crystalline micronisate, process for the manufacture thereof and use thereof for the preparation of a medicament
AU2003234929A1 (en) Therapeutic agent for diabetes
AU2003279442A8 (en) 2-thiohydantoine derivative compounds and use thereof for the treatment of diabetes
HK1085920A1 (en) Use of dihydroimidazolones for the manufacture of a medicament for the treatment of epilepsy in dogs
AU2003252182A1 (en) Therapeutic treatment for the metabolic syndrome and type 2 diabetes
AU2003203146A1 (en) Use of glp-1 compound for treatment of critically ill patients
IL165242A0 (en) Treatment for diabetes
IL162853A0 (en) The use of melagatran for the manufacture of a medicament for the treatment of type 1 diabetes mellitus
AU2003303217A8 (en) Use of substituted 2,5-diamidoindoles for the treatment of urological diseases
AU2003296545A1 (en) Use of a trpm8-activating substance for the treatment of tumours
PL378537A1 (pl) Zastosowanie propionylo L-karnityny do otrzymywania leku do leczenia glaukomii
HUP0400060A2 (hu) Acetil-L-karnitin alkalmazása biotinnal együtt, II típusú, inzulinrezisztens diabétesz mellituszban szenvedő betegek kezelésére
AU2003209542A8 (en) Use of s-substituted l-crysteine for the manufacture of a medicament for the treatment of dermatological disorders
AU2002307327A1 (en) Use of an ampa receptor potentiator for the manufacture of a medicament for the treatment of type 2 diabetes
IL153279A0 (en) Thiazolidinedione salt for treatment of diabetes mellitus
AU2002311141A1 (en) The use of hydrochloric acid in the preparation of a medicament for the treatment of tumour
AU2003232698A1 (en) Use of a n,n'-dibenzyl-thiourea as medicine